Argus Research Maintains Buy on AstraZeneca, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Argus Research has maintained its Buy rating on AstraZeneca and raised the price target from $80 to $85.
May 30, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has maintained its Buy rating on AstraZeneca and increased the price target from $80 to $85, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from Argus Research suggest positive sentiment and confidence in AstraZeneca's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100